Search results for "PROGRESS"

showing 10 items of 1620 documents

Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV …

1997

A multicentric, prospective phase III study was carried out with the aim of testing the so-called 'worst drug rule' hypothesis, which suggests the use of an effective but 'less active' regimen that first eradicates tumoral cells resistant to a second effective and 'more active' regimen. With respect to this hypothesis, we considered the cisplatin plus vinorelbine regimen (CCDP/VNR) as the more active regimen compared with the non-cisplatin-containing regimen of ifosfamide plus high-dose epirubicin (IFO/EPI). Thus, a randomized study was carried out to compare the sequencial strategy of three cycles of CDDP/VNR followed by three cycles of IFO/EPI with the opposite sequence in advanced non-sm…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsUrologyVinblastineVinorelbineDrug Administration ScheduleCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideProspective StudiesNeoplasm MetastasisLung cancerProspective cohort studyAgedEpirubicinNeoplasm StagingMesnaIfosfamidePerformance statusbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurgeryRegimenOncologyDisease ProgressionFemaleCisplatinbusinessResearch Articlemedicine.drugEpirubicinBritish Journal of Cancer
researchProduct

Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.

1995

Interferon alpha-2a (IFN-alpha) and folinic acid (FA) have been shown to modulate the cytotoxic effects of 5-fluorouracil (5-FU) in the treatment of cancer. A phase II study was initiated to evaluate the effect of a combination of 5-FU/FA/IFN-alpha in patients with advanced pancreatic cancer. Sixty previously untreated patients with advanced adenocarcinoma of the pancreas were treated with 500 mg m-2 FU via an intravenous bolus 1 h after the initiation of a 2 h infusion of 500 mg m-2 FA. Before starting the FA infusion, 6 million units (MU) of IFN-alpha was administered subcutaneously. The treatment was repeated once a week. Of 57 evaluable patients, eight (14%) had a partial response (PR),…

AdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentLeucovorinAlpha interferonAdenocarcinomaInterferon alpha-2GastroenterologyFolinic acidInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInterferon alfaAgedChemotherapybusiness.industryInterferon-alphaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryPancreatic NeoplasmsOncologyFluorouracilFemaleFluorouracilbusinessProgressive diseasemedicine.drugResearch ArticleBritish Journal of Cancer
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma.

2002

Abstract Purpose: To evaluate the effectiveness of stereotactic fractionated radiotherapy (SFRT) in the treatment of optic nerve sheath meningioma (ONSM). Methods and Materials: Between 1994 and 2000, a total of 39 patients with either primary ( n = 15) or secondary ( n = 24) ONSM were treated with SFRT and received a median total tumor dose of 54 Gy using 1.8 Gy/fraction. Results: The radiographic response to SFRT was documented in all patients as stable disease (no change) except for 1 patient with a partial response. After a median follow-up of 35.5 months, all patients with ONSM were alive without recurrence. The visual fields and visual acuity were improved in 6 of 15 and 1 of 16 exami…

AdultMaleCancer Researchmedicine.medical_specialtyVisual acuityTime FactorsFractionated radiotherapyErythemaAdolescentRadiographyRadiosurgerymedicineHumansRadiology Nuclear Medicine and imagingIn patientAge of OnsetAgedAged 80 and overRadiationbusiness.industryStandard treatmentOptic Nerve NeoplasmsDose fractionationMiddle Agedmedicine.diseaseSurgeryOptic nerve sheath meningiomaTreatment OutcomeOncologyDisease ProgressionFemaleRadiologyDose Fractionation Radiationmedicine.symptombusinessMeningiomaFollow-Up StudiesInternational journal of radiation oncology, biology, physics
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

2004

Contains fulltext : 57114.pdf (Publisher’s version ) (Closed access) Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication.…

AdultMaleCancer Researchmedicine.medical_specialtyrenal cell carcinomaRecombinant Fusion ProteinsPhases of clinical researchAntineoplastic AgentsGastroenterologyClinicalMonoclonal antibody G250Renal cell carcinomaInternal medicinemedicineCarcinomaHumansProspective StudiesCarcinoma Renal CellAgedbusiness.industryGirentuximabAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]CA-IXMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryClinical trialTreatment OutcomeOncologymonoclonal antibodyAntigens SurfaceFemaleimmunotherapybusinessWX-G250Progressive diseasemedicine.drugKidney disease
researchProduct

Malondialdehyde in early phase of acute pancreatitis

2011

Aims: to assess oxidative stress in acute pancreatitis, its evolution over time and its relationship with the severity of the disease. Methods: during a two-year period, patients with acute pancreatitis with less than 24 hours of pain were evaluated. Serum was obtained the first, second and fourth day from admittance, if complications were detected, and after recovery. Malondialdehyde was determined by high performance liquid chromatography. Twenty healthy volunteers constituted the control group. Malondialdehyde between groups was compared with Mann-Whitney and Kruskal-Wallis tests; malondialdehyde evolution was studied with Wilcoxon test. Results: one hundred and sixty-nine patients were …

AdultMaleComplicationsmedicine.disease_causeSeverity of Illness Indexchemistry.chemical_compoundMalondialdehydeHealthy volunteersHumansMedicineProspective StudiesChromatography High Pressure LiquidAgedAged 80 and overbusiness.industryGastroenterologyGeneral MedicineMiddle AgedPrognosismedicine.diseaseMalondialdehydeAcute pancreatitisOxidative StressPancreatitischemistryOxidative stressCase-Control StudiesAnesthesiaAcute DiseaseDisease ProgressionAcute pancreatitisPancreatitisFemalebusinessEarly phaseBiomarkersOxidative stressRevista Española de Enfermedades Digestivas
researchProduct

Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene.

2000

Emery-Dreifuss muscular dystrophy (EDMD) is characterized by early contractures of the elbows and Achilles tendons, slowly progressive muscle wasting and weakness, and life-threatening cardiomyopathy with conduction blocks. We recently identified LMNA encoding two nuclear envelope proteins, lamins A and C, to be implicated in the autosomal dominant form of EDMD. Here, we report on the variability of the phenotype and spectrum of LMNA mutations in 53 autosomal dominant EDMD patients (36 members of 6 families and 17 sporadic cases). Twelve of the 53 patients showed cardiac involvement exclusively, although the remaining 41 all showed muscle weakness and contractures. We were able to identify …

AdultMaleContractureAdolescentGenotypeBiopsyNonsense mutationDNA Mutational AnalysisEmerinMutation MissenseLaminopathyBiologyLMNACardiovascular Physiological PhenomenamedicineMissense mutationHumansEmery–Dreifuss muscular dystrophyMuscular dystrophyAge of OnsetChildCreatine KinasePhysical ExaminationMuscle contractureAgedGenes DominantGeneticsMuscle WeaknessMyocardiumNuclear ProteinsHeartMiddle Agedmedicine.diseaseLamin Type ALaminsMuscular Dystrophy Emery-DreifussPedigreeMuscular AtrophyPhenotypeNeurologyDisease ProgressionFemaleNeurology (clinical)Gene DeletionAnnals of neurology
researchProduct

Profile of the Immune and Inflammatory Response in Individuals With Prediabetes and Type 2 Diabetes.

2015

OBJECTIVE The inflammatory and immune systems are altered in type 2 diabetes. Here, the aim was to profile the immune and inflammatory response in subjects with prediabetes and diabetes in a large population-representative sample. RESEARCH DESIGN AND METHODS In total, 15,010 individuals were analyzed from the population-based Gutenberg Health Study. Glucose status was classified according to HbA1c concentration and history of diagnosis. All samples were analyzed for white blood cells (WBCs), granulocytes, lymphocytes, monocytes, platelets, C-reactive protein (CRP), albumin, fibrinogen, and hematocrit. Interleukin-18 (IL-18), IL-1 receptor antagonist (IL-1RA), and neopterin concentrations w…

AdultMaleEndocrinology Diabetes and MetabolismPopulationType 2 diabetesComorbidityHematocritFibrinogenPrediabetic Statechemistry.chemical_compoundImmune systemRisk FactorsDiabetes mellitusInternal MedicinemedicineHumansPrediabeteseducationAgedAdvanced and Specialized NursingInflammationeducation.field_of_studymedicine.diagnostic_testbusiness.industryImmunityNeopterinMiddle Agedmedicine.diseaseC-Reactive ProteinchemistryDiabetes Mellitus Type 2Cardiovascular DiseasesImmunologyDisease ProgressionFemalebusinessBiomarkersmedicine.drugDiabetes care
researchProduct

Spinal ependymoma in adults: a multicenter investigation of surgical outcome and progression-free survival

2018

OBJECTIVESpinal ependymomas are rare glial neoplasms. Because their incidence is low, only a few larger studies have investigated this condition. There are no clear data concerning prognosis and therapy. The aim of the study was to describe the natural history, perioperative clinical course, and local tumor control of adult patients with spinal ependymomas who were surgically treated under modern treatment standards.METHODSThe authors performed a multicenter retrospective study. They identified 158 adult patients with spinal ependymomas who had received surgical treatment between January 2006 and June 2013. The authors analyzed the clinical and histological aspects of these cases to identif…

AdultMaleEpendymomaMicrosurgerymedicine.medical_specialtyAdolescentSpinal intradural tumormedicine.medical_treatmentYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceNeoplasmsBiomarkers TumormedicineHumansSpinal Cord NeoplasmsProgression-free survivalGrading (tumors)AgedRetrospective StudiesAged 80 and overSpinal cordbusiness.industryIncidence (epidemiology)Retrospective cohort studyGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseProgression-Free Survivalddc:616.8SurgeryRadiation therapyKi-67 AntigenLocalOncologyEpendymomaTumor progression030220 oncology & carcinogenesisFemaleRadiotherapy AdjuvantNeoplasm Recurrence Localbusiness030217 neurology & neurosurgeryFollow-Up StudiesJournal of Neurosurgery: Spine
researchProduct